ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
3.890
+0.080 (2.10%)
At close: Nov 13, 2026, 4:00 PM EST
3.850
-0.040 (-1.03%)
After-hours: Nov 13, 2026, 7:30 PM EST

ARS Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
122.1484.2889.150.031.325.51
Revenue Growth
-14.45%-5.46%297063.33%-97.72%-76.10%-69.13%
Cost of Revenue
66.1233.620.5620.2717.1220.27
Gross Profit
56.0150.6768.59-20.24-15.8-14.77
Selling, General & Admin
253.26230.1271.6847.2818.664.69
Operating Expenses
253.26230.1271.6847.2818.664.69
Operating Income
-197.25-179.45-3.08-67.52-34.46-19.45
Interest Expense
-10.02-2.6----0.8
Interest & Investment Income
7.3110.6711.37---
Other Non Operating Income (Expenses)
---6.011.120.01
EBT Excluding Unusual Items
-199.95-171.388.29-61.51-33.34-20.24
Gain (Loss) on Sale of Investments
---6.85-0.29-
Gain (Loss) on Sale of Assets
---0.3--
Pretax Income
-199.95-171.388.29-54.37-34.68-20.24
Income Tax Expense
-0.08-0.080.29---
Net Income
-199.87-171.38-54.37-34.68-20.24
Net Income to Common
-199.87-171.38-54.37-34.68-20.24
Net Income Growth
------
Shares Outstanding (Basic)
999997954029
Shares Outstanding (Diluted)
9999102954029
Shares Change
1.19%-3.74%7.54%138.30%38.39%42.81%
EPS (Basic)
-2.01-1.740.08-0.57-0.87-0.70
EPS (Diluted)
-2.01-1.740.08-0.57-0.87-0.70
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-183.07-171.2112.99-59.44-40.28-17.62
Free Cash Flow Per Share
-1.84-1.740.13-0.62-1.01-0.61
Gross Margin
45.86%60.13%76.94%---268.20%
Operating Margin
-161.50%-212.92%-3.46%-225066.67%-2618.54%-353.32%
Profit Margin
-163.64%-203.25%8.97%-181216.67%-2635.41%-367.65%
Free Cash Flow Margin
-149.89%-203.14%14.57%-198136.67%-3060.56%-319.94%
EBITDA
-195.6-178.08-3-67.45-34.43-19.24
EBITDA Margin
-160.15%-211.30%-3.37%---
D&A For EBITDA
1.651.370.080.070.030.21
EBIT
-197.25-179.45-3.08-67.52-34.46-19.45
EBIT Margin
-161.50%-212.92%-3.46%---
Effective Tax Rate
--3.48%---
Revenue as Reported
122.1484.2889.150.03--
SEC Filings: 10-K · 10-Q